BioSpace News Archive

Pharm Country

Datopotamab Deruxtecan Showed Encouraging and Durable Efficacy in Patients with Heavily Pretreated HR Positive, HER2 Low or Negative Metastatic Breast Cancer

Initial results from the TROPION-PanTumor01 phase 1 trial of datopotamab deruxtecan showed encouraging and durable efficacy in patients with heavily pretreated hormone receptor positive, HER2 low or HER2 negative unresectable or metastatic breast cancer.

December 8, 2022
·
9 min read
BioCapital

Innovent Presents Phase Ib Clinical Data Update of IBI110 (Anti-LAG-3 Monoclonal Antibody) at the 2022 European Society For Medical Oncology Immuno-Oncology Congress

Innovent Biologics, Inc. announced that updated clinical data of IBI110 in advanced squamous non-small cell lung cancer is presented at the 2022 European Society for Medical Oncology Immuno-Oncology Congress, held Dec 7-9, 2022.

December 8, 2022
·
8 min read
BioCapital

Innovent Presents Phase Ib Clinical Data of IBI939 (Anti-TIGIT Monoclonal Antibody) in Previously Untreated PD-L1-selected NSCLC at the 2022 European Society For Medical Oncology Immuno-Oncology Congress

Innovent Biologics, Inc. announced that clinical data of IBI939 is presented at the 2022 European Society for Medical Oncology Immuno-Oncology Congress, Dec 7-9, 2022.

December 8, 2022
·
7 min read
BioMidwest

Myriad Genetics Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model

Myriad Genetics, Inc., a leader in genetic testing and precision medicine, presented results from a longitudinal study validating RiskScore as a well-calibrated and more accurate predictor of breast cancer risk than a standard-of-care risk assessment alone.

December 8, 2022
·
3 min read
Biotech Beach

Prometheus Biosciences, Inc. Announces Pricing of Public Upsized $500 Million Offering of Common Stock

Prometheus Biosciences, Inc. announced the pricing of an underwritten offering of 4,545,455 shares of its common stock at a price to the public of $110 per share.

December 8, 2022
·
4 min read
Pharm Country

AmerisourceBergen Announces Common Share Repurchase From Walgreens Boots Alliance

AmerisourceBergen Corporation announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount of approximately $200 million in concurrence with Walgreens Boots Alliance’s sale of AmerisourceBergen shares pursuant to Rule 144.

December 8, 2022
·
1 min read
Genetown

Replimune Announces Pricing of Public Offering - December 09, 2022

Replimune Group, Inc., a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, announced the pricing of its public offering of 5,374,486 shares of its common stock at a public offering price of $23.50 per share.

December 8, 2022
·
5 min read